Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novartis, Array In MEK Inhibitor Pact
by Lisa M. Jarvis
April 26, 2010
| A version of this story appeared in
Volume 88, Issue 17
Novartis has agreed to pay Boulder, Colo.-based Array BioPharma up to $477 million for access to ARRY-162, a MEK inhibitor in Phase I trials as a treatment for solid tumors. Array snags a $45 million up-front payment in the deal, which includes backup MEK inhibitors. The U.S. company will also share in the development costs of ARRY-162 in exchange for a bigger slice of sales if the drug is commercialized. MEK is one of several protein kinases in a cell signaling pathway associated with cancer cell proliferation and survival.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X